Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
You may also be interested in...
Novo Nordisk aims to offset US pricing pressures with increased cost management, freeing investment for key growth drivers like Ozempic and oral Semaglutide.
But elephant in the room – the coming stream of readouts from Phase III PIONEER trials on oral semaglutide in Type 2 diabetes – gets little mention at first-quarter update.
Planned next generation of oral semaglutide 'is in the early research stage', Lars Fruergaard Jorgensen tells Scrip.